On 18 December 2006, orphan designation (EU/3/06/421) was granted by the European Commission to Napp Pharmaceuticals Research Limited, United Kingdom, for forodesine hydrochloride for the treatment of acute lymphoblastic leukaemia.
The name of the sponsor changed to Mundipharma Research Limited in 2007.
The sponsorship was transferred to Mundipharma Corporation (Ireland) Limited, Ireland, in April 2019.
Treatment of acute lymphoblastic leukaemia
|Orphan designation status||
|EU designation number||
|Date of designation||
Documents related to this orphan designation evaluation
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
EU register of orphan medicines
The list of medicines that have received an orphan designation in the EU is available on the European Commission's website: